Free Trial

Daxor (DXR) Competitors

Daxor logo
$10.14 +0.14 (+1.40%)
As of 07/25/2025 02:34 PM Eastern

DXR vs. SGHT, TLSI, INGN, PROF, KRMD, BSGM, LNSR, ELMD, PDEX, and PTHL

Should you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), Inogen (INGN), Profound Medical (PROF), KORU Medical Systems (KRMD), Biosig Technologies (BSGM), LENSAR (LNSR), Electromed (ELMD), Pro-Dex (PDEX), and Pheton (PTHL). These companies are all part of the "medical equipment" industry.

Daxor vs. Its Competitors

Sight Sciences (NASDAQ:SGHT) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Daxor has lower revenue, but higher earnings than Sight Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sight Sciences$79.87M2.26-$51.51M-$0.98-3.56
Daxor$2.13M23.02N/AN/AN/A

55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 30.9% of Sight Sciences shares are held by insiders. Comparatively, 59.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Daxor has a net margin of 0.00% compared to Sight Sciences' net margin of -63.24%. Daxor's return on equity of 0.00% beat Sight Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sight Sciences-63.24% -54.62% -34.92%
Daxor N/A N/A N/A

In the previous week, Sight Sciences had 1 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Sight Sciences and 2 mentions for Daxor. Daxor's average media sentiment score of 0.94 beat Sight Sciences' score of 0.46 indicating that Daxor is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sight Sciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Daxor
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sight Sciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.

Sight Sciences presently has a consensus price target of $3.93, suggesting a potential upside of 12.70%. Daxor has a consensus price target of $25.00, suggesting a potential upside of 146.55%. Given Daxor's stronger consensus rating and higher possible upside, analysts clearly believe Daxor is more favorable than Sight Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sight Sciences
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.29
Daxor
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Daxor beats Sight Sciences on 8 of the 13 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXR vs. The Competition

MetricDaxorMED IndustryMedical SectorNASDAQ Exchange
Market Cap$48.37M$3.78B$5.70B$9.50B
Dividend YieldN/A1.34%4.69%4.01%
P/E RatioN/A32.7428.1020.06
Price / Sales23.02123.93428.7189.10
Price / CashN/A21.9036.2258.56
Price / BookN/A4.408.665.87
Net IncomeN/A$189.47M$3.25B$258.55M
7 Day Performance12.67%2.10%4.22%3.73%
1 Month Performance5.30%-4.24%10.51%11.75%
1 Year Performance12.67%-2.92%34.40%18.02%

Daxor Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXR
Daxor
3.9714 of 5 stars
$10.14
+1.4%
$25.00
+146.5%
+12.0%$48.37M$2.13M0.0037
SGHT
Sight Sciences
1.5411 of 5 stars
$3.57
+4.1%
$3.93
+10.2%
-56.5%$177.32M$79.87M-3.64210Upcoming Earnings
TLSI
TriSalus Life Sciences
2.841 of 5 stars
$4.50
-1.5%
$10.75
+138.9%
-20.1%$172.92M$29.43M-4.02106News Coverage
Gap Down
INGN
Inogen
4.2482 of 5 stars
$6.34
+0.8%
$11.00
+73.5%
-29.9%$169.12M$335.70M-5.511,030
PROF
Profound Medical
2.6593 of 5 stars
$5.87
+5.8%
$11.00
+87.4%
-47.9%$166.79M$11.86M-4.81150News Coverage
KRMD
KORU Medical Systems
2.8847 of 5 stars
$3.43
-0.9%
$4.50
+31.2%
+39.2%$159.65M$33.65M-31.1880Positive News
BSGM
Biosig Technologies
1.9472 of 5 stars
$6.10
+5.9%
$10.00
+63.9%
+964.4%$157.22M$40K0.0050Gap Up
High Trading Volume
LNSR
LENSAR
1.2718 of 5 stars
$13.07
-1.9%
$15.00
+14.8%
+143.0%$157.07M$57.07M-2.69110Positive News
ELMD
Electromed
1.2781 of 5 stars
$18.69
+3.1%
$33.50
+79.2%
+26.9%$156.73M$61.44M24.92160News Coverage
Analyst Forecast
Analyst Revision
PDEX
Pro-Dex
2.4778 of 5 stars
$47.67
+2.2%
$56.00
+17.5%
+159.1%$152.16M$53.84M17.03140
PTHL
Pheton
N/A$22.50
-0.5%
N/AN/A$148.82M$450K0.0011Positive News
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:DXR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners